Daniel: Bringing healthcare to the streets for the vulnerable

(15:35)

Austraordinary Heroes Introduction

(30)

Austraordinary Heroes Introduction

(1:56)

Let's change the story for people living with obesity. Join us!

(1:30)

🎉 ¡Año Nuevo Chino! Ana retoma sus propósito y lo intenta de nuevo 🐉✨

(28)

🎉 ¡Año Nuevo Chino! Ana retoma sus propósito y lo intenta de nuevo 🐉✨

(1:14)

Join us for a career within Manufacturing

(1:42)

Join us for a career within Engineering

(1:59)

Meet Brittany, Engineering a Rewarding Career in Manufacturing

(1:25)

Meet Charlene, Leaders on the Line in U.S. Manufacturing

(1:12)

How to use NovoPen 4

(6:46)

The spirit of our founders: The values and mindsets that created Novo Nordisk a century ago

(24:15)

Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly

(3:58)

Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging

(4:8)

CEO DIALOGUE #35 - Lars Fruergaard Jørgensen, Novo Nordisk

(49:8)

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company

(19:20)

Novo Nordisk CEO expects same growth for 2025

(3:1econd)

Novo Nordisk (Ozempic)

(3:45:26)

Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst

(6:22)

3-Stock Lunch: Intel, Sherwin-Williams \u0026 Novo Nordisk

(1:52)

Novo Nordisk CEO shares his outlook for Wegovy pricing in the U.S.

(1:14)

Novo Nordisk Aktie -48% CRASH-UPDATE: Ich kaufe JETZT für 500.000 Euro den Marktführer

(27:49)

How Novo Nordisk built an empire selling diabetes and weight-loss drugs

(2:16)

Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

(4:35)

Novo Nordisk plunges after obesity drug trial disappoints | REUTERS

(1:31)

CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field

(4:8)

NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortages

(4:29)

Novo Nordisk CEO Lars Fruergaard Jørgensen on Q4 results, Wegovy demand and drug pipeline outlook

(7:56)

BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

(4:1econd)